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Women's evolution for nurturing and fat accumulation, which historically yielded health and longevity advantages
against scarcity, may now be counteracted by increasing risks in the obesogenic environment, recently shown by
narrowing gender health gap. Women's differential metabolism/disease risks, i.e. in fat accumulation/distribution,
exemplified during puberty/adolescence, suggest gender dimorphism with obesity outcomes. Women's higher
body fat percentage than men, even with equal body mass index, may be a better risk predictor. Differential
metabolic responses to weight-reduction diets, with women's lower abdominal fat loss, better response to high-
protein vs. high-carbohydrate diets, higher risks with sedentariness vs. exercise benefits, and tendency toward
delayed manifestation of central obesity, metabolic syndrome, diabetes, cardiovascular disease, and certain cancers
until menopause—but accelerated thereafter—suggest a need for differing metabolic and chronological
perspectives for prevention/intervention. These perspectives, including women's differential responses to lifestyle
changes, strongly support further research with a gender nutrition emphasis within predictive, preventive, and
personalized medicine.
Keywords: Women, Gender, Nutrition, Obesity, Metabolic syndrome, Life expectancy, Sexual dimorphism, n-6/n-3
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Introduction
Women's evolution vs. food scarcity, which necessitated
effective fat accumulation for preparing available energy
and nutrients for fertility and feeding/caring of offspring,
has long translated to a health and longevity advantage.
However, this may now be counteracted by the ‘obeso-
genic’ environment.
Pubertal gender dichotomy of girls accumulating fat vs.
boys losing fat and growing muscles and height [1,2] illus-
trates an obesity-related aspect of gender differential adap-
tation to scarcity and women's advantage. However,
extreme changes in the environment, particularly increas-
ing food availability/accessibility and reduced mobility, as
well as increased calories and reduced nutrient density inCorrespondence: nivnet@inter.net.il
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reproduction in any medium, provided the orprocessed foods—together defined as an obesogenic envi-
ronment—have conferred a great burden of overconsump-
tion and obesity (Figure 1), unrelated to nutritional
sufficiency/deficiency [3]. This may be especially critical in
females, given their innate tendency toward fat accumula-
tion and risks from nutrient-exhausting pregnancy/lacta-
tion, and resultant deficiency disorders [4-6]. This new
metabolic ‘mismatch’ in women could greatly contribute
to the recent decline in the gender gap in life expectancy
(LE) and in healthy LE (HLE), associated with a slowed
increase in female LE and HLE compared to males [7-10]
(Figure 2), that is gradually narrowing the gender gap
[11,12] resulting from increases in the environmental
burden on women's health and consequently on the
healthcare system.
Beyond the general perspective that the declining gender
LE gap was associated primarily with changes in smoking
and alcohol use [14], a new perspective on women's healthThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Prevalence of morbid obesity among adults aged 16+ years: Health Survey for England 1993–2010 [13]. The rise of morbid
obesity (≥40 kg/m2) has been led by women in developed, high-income countries, i.e. in the UK where between 1993 and 2010, the prevalence
of morbid obesity was consistently higher among women (increasing from 1.5% in 1993 to 3.8% in 2010) than among men (increasing from 0.3%
in 1993 to 1.6% in 2010).
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timetables, i.e. earlier and higher risk of lifelong obesity,
differential fat distribution and risk measures, i.e. body
mass index (BMI), waist circumference (WC), and delayed
risk manifestation to postmenopausal age, which is asso-
ciated with reduced estrogen protection. Here, predictive,
preventive, personalised nutrition should take a lead—Figure 2 Gender-environment interaction effect on obesity, health ris
Obesogenic (increased calories and reduced mobility) conditions in Wester
high mobility, have conferred a great burden of overconsumption and obe
lifelong body fat percentage could make them more vulnerable and have
(females-males, years) of life expectancy (LE) and healthy LE (HLE) years.before the risk manifestation—according to the specific
timing of physiological events, critical periods, early pro-
gramming, and their metabolic patterns [15].
The present paper shows women's leading role in the
obesity epidemic, which could potentially become their
leading lifelong risk factor for disability and mortality.
As fewer metabolic studies regarding disease risk haveks, life expectancy (LE), and healthy life expectancy (HLE).
n lifestyles, compared to historically restrictive dietary conditions and
sity. Women's innate tendency toward fat accumulation and higher
contributed to the recent decline in the gender gap
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need for better understanding of women's specific nu-
tritional risks resulting from environmental changes.
Approaching metabolic dimorphism as a major factor in
gender nutrition is now becoming crucial for designing
and enhancing healthcare quality and effectiveness of per-
sonalised medicine [16], as comprehensively described in
the recent White Paper of the European Association for
Predictive, Preventive and Personalised Medicine [17].
Women's declining advantage in health and life
expectancy
Though women still outlive men throughout the world,
their LE advantage seen in the early twentieth century is
now declining, especially in Western countries [11,12].
For example, in France, previously a gender gap leader
(7.66 years), the LE gap stopped increasing in the 1980s
and began decreasing in recent years, which was partially
attributed to a reduction in cardiovascular disease (CVD)
and lung cancer mortality in men, as found in a few
European countries [18]. In Norway during the last 25
years, the LE increased by ≈6 years in men and only ≈3
years in women, resulting in a 2.5-year reduction in
gender LE gap [7]. In the UK, between 1990 and 2002, the
average annual rate of improvement in mortality was
≈30% higher in men than in women [8]. Similar trends
had previously been observed in the USA, Sweden,
England and Wales, Hungary, Sweden, Australia [19], and
Canada [20], though not seen in Japan [21].
Whereas healthy LE has declined in women more than
in men, i.e. between 1989 and 2000 by 4.3 years vs. 0.8
years, respectively [18], their unhealthy LE has increased,
i.e. women with heart disease have greater LE at 50 years
than men, 7.9 vs. 6.7 years, though women's heart
disease onset tends to be delayed by ≈3.0 years and heart
attacks by 4.4 years compared to men [22]. Similarly,
HLE in Italian women was reduced by 2 years compared
to their previous advantage, with resultant equal LE at
age 65 of ≈7 years, for both genders [9].
A gender health-survival paradox of women's higher mor-
bidity rates despite longer LE—as found in Western coun-
tries—is also found in Singapore, where at age 65, women's
remaining life yields more disabilities, such as hypertension,
bone/joint problems, walking difficulties, and visual and
functional impairments compared to same-aged men [10].
The above and further population studies show that
women's HLE is compromised beyond their declining lon-
gevity, which may necessitate specific preventive strategies.
Obesity-related decreased life expectancy and increased
disability
Many studies have demonstrated that obese individuals suf-
fer an elevated risk of death [23] and that a high level of
obesity is contributing to reduced LE, i.e. in the USA, LE isfalling below that of most other industrialised countries,
with a ranking of 32nd in the world in 2008 [24], concur-
rent with the highest per capita expenditure on healthcare
in the world [25]. Obesity was associated with reduced US
LE at age 50 years by 1.54 and 1.85 years for women and
men, respectively, a shortfall (by 42% and 67%) relative to
countries with higher LEs, and a higher (by 25% and 40%)
effect on LE than in Canada and the UK, the two countries
with the next-highest rates of obesity [26]. Excess US BMI
was responsible for approximately 95 million years of life
lost (YLL), with women accounting for more than two-
thirds [27], and their obesity-associated reduction in lon-
gevity was higher than that in other countries [28], possibly
because of younger age and higher severity of obesity. Of
note, an increase in two BMI units in overweight popula-
tions was estimated to decrease lifespan, i.e. in men by 1
year, comparable to a 10% increase in the prevalence of
smoking [27,29].
Beyond the effect of obesity (BMI of 30–34.9 kg/m2) on
reducing LE, it was also shown to reduce disability-free LE
[30], i.e. among men by 2.7 years, concurrent with increas-
ing LE with disability by 2.0 years, compared to changes
among women by 3.6 years and 3.2 years, respectively, and
overweight (BMI 25–29.9) increased LE with disability for
women only, by 2.1 years. Women's longest HLE was
shown at BMI of 18.5–22.9, men's at 25–29.9 (Figure 3)
and decreased thereafter, together with increasing LE with
disabilities [31].
Women's lead in the obesity epidemic
Worldwide obesity has more than doubled since the
1980s, and rates continue to push upward throughout
the world. By 2008, an estimated 1.46 billion adults and
170 million children worldwide were overweight (BMI
≥25 kg/m2) or obese (BMI ≥30), with higher rates in
women, though varying widely by country. For example,
an estimated 18% of women in France are obese, in
Greece 26%, in Mexico 35%, and in Saudi Arabia 44%; in
contrast, the percentage in both Japan and China was
3% [32]. In the USA, with an overall prevalence of 68.3%
overweight [28] and 33.9% obesity, women show higher
rates than men of severe obesity (BMI ≥35, 17.8% vs.
10.7%) and morbid obesity (BMI ≥40, 7.2% vs. 4.2%)
differences of 78% and 71.4%, respectively [33].
However, longitudinal trends previously showing
women's increased obesity prevalence—that initially pre-
ceded men's—later slowed, leading to a decline in the
gender gap, with women's prevalence over the last 12-
year period increasing by only 6.3% vs. men's by 17.1%
(1999–2008) [28].
Women's body fat percentage vs. BMI as risk-predictive
Though the definition of obesity is uniform for women
and men, women typically have higher body fat percentage
Figure 3 Life expectancy at age 55 with/without disability in
activities of daily living (univariate analysis). Error bars represent
95% confidence intervals of disability-free and total life expectancy
[31]. The average LE at 55 years of age is 24.0 years for men and
28.2 years for women (excluding underweight individuals). The
longest disability-free LE was found with a BMI between 18.5 and
22.9 for women and 25.0 and 29.9 for men. Mild obesity
(BMI 30–34.9) did not shorten total LE, but at age 55, it shortened
disability-free life to 2.9 years for males and 4.3 years for females
compared to high normal weight (BMI 23–24.9). Severely obese men
live an average of 6.0 years less free from ADL disability and women
for 8.4 less years. For men, low normal weight (BMI 18.5-22.9) lowers
both total and disability-free LE.
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point [34]. In NHANES III, women's average body fat per-
centage, at 20–80 years, was higher than men's by 44%
(34.9% vs. 24.3%, respectively), despite similar correspon-
ding BMIs (26.27 vs. 26.83). Thus, women's BMI may not
accurately reflect but rather may partially mask their ac-
tual obesity [34]. This may lead women to a condition of
‘metabolically obese/normal weight’—already at a young
age—wherein despite having a normal BMI, they display
body composition and metabolic characteristics that may
predispose them to development of metabolic syndrome
(MetS) [35].
Women's tendency toward obesity compared to men's
is manifested by several metabolic patterns, includinglower fat oxidation, especially postprandially, with more
efficient fat storage [36]; lower resting energy expend-
iture rates [37-39]; higher response to insulin (as shown
in glucose metabolism in both the liver and muscle) and
to an exercise with weight loss diet combination [40];
higher adipose tissue-expanding capacity with long-term
high-fat feeding [41]; and higher leptin levels, associated
with higher inflammatory (C-reactive protein [CRP] and
MetS risk, that were independent of adiposity [42].
In metabolically obese normal-weight women, there is
a tendency toward greater central fat mass, associated
with reduced insulin sensitivity [43,44], shown even with
normal glucose tolerance [45]. Further, they may have
smaller particles of low-density lipoprotein (LDL); higher
concentrations of oxidised LDL, TNF-alpha, interleukin
(IL)-6, and leptin; and lower plasma adiponectin than
women with normal visceral adiposity [46], all of which
contribute to increased obesity-related disease risk. Such
hidden obesity was found in underactive Western women
and in Asian women, who were observed to have a higher
body fat percentage for each BMI level, potentially asso-
ciated with prominent abdominal obesity, higher intra-
muscular and liver fat content, and predisposition to
insulin resistance and diabetes mellitus [47].
According to body fat percentage, the prevalence of ‘at
risk’ (preobese or obese) among normal BMI men and
women was 69% and 85%, respectively, suggesting that
screening for adiposity in individuals with a normal
BMI could further identify those at higher risk for
cardiometabolic disturbances and cardiovascular mortality,
especially among women, as the false-negative classifica-
tion of BMI was stronger for women than for men [48].
Together, the above places women at risk for greater
obesity and sequelae, especially with increasing exposure
to the global obesogenic environment.
Women's earlier and greater predisposition to obesity
Women's obesity tendencies begin much earlier than men's,
already in the womb [49]. Girls aged ≤10 years have 28%
greater total fat and 30% more subcutaneous fat than boys,
with similar amounts of visceral fat [1]. Dimorphism in
total fat mass and in fat tissue distribution (visceral vs. sub-
cutaneous) progresses from prepuberty [50], where body fat
percentage declines in boys as they gain muscle, but
increases in girls [2]; correspondingly, early-maturing boys
are thinner, whereas early-maturing girls are fatter [51], and
menarche seems to occur most frequently with ≥17% body
fat [52]. Further, adult women's age of increasing obesity is
much earlier than men's, rates higher at 20–39 years of age
by 23.7% for BMI ≥30 and 100% for BMI ≥35 and at 40–59
years by 11.4% and 68.1%, respectively [28].
These epidemiological trends and gender differences
underscore the importance of defining sex-specific char-
acteristics and women's earlier and stricter prevention
Figure 4 Overview of insulin resistance induced by estrogen
deficiency, and subsequent disturbances in metabolic tissues
[54]. As estrogen participates in the regulation of glucose
homeostasis, estrogen deficiency, like that seen in post menopausal
women, is strongly linked to the development of insulin resistance
and subsequent impairments manifested in the pancreas, liver, and
muscle and adipose tissue, key organs influencing risk of chronic
metabolic disease.
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MetS, diabetes mellitus, coronary heart disease (CHD),
and cancer [53].
Women's delayed risk manifestation: hormonal schedule vs.
obesity pressure
Estrogen and estrogen receptors (ER) are well-known reg-
ulators of several aspects of metabolism, including glucose
and lipid metabolism, and impaired estrogen signalling is
associated with the development of metabolic diseases.
Here, ERα seems to play a protective role in insulin and
glucose metabolism, through effects on the liver, adipose
tissue, muscle, and pancreatic β cells and on central regu-
lation of food intake and energy expenditures. ERβ, on the
other hand, has the potential to negatively influence insu-
lin and glucose metabolism by impairment of adipose
tissue function, probably through augmented PPARγ sig-
nalling, and declined expression of GLUT4 in the muscle
[54]. Several epidemiological and prospective studies have
linked estrogen and the ER to various aspects of metabolic
disease and to estrogen protection in premenopausal
women.
The onset of menopause dramatically increases the risk
for women to develop disease states coupled to the MetS,
such as obesity, CVD, and type 2 diabetes. Here, estrogen
deficiency is strongly linked to the development of insulin
resistance and subsequent manifestations in various meta-
bolic tissues (Figure 4) that could be repaired by hormone
replacement therapy [54]. For example, estrogen's inverse
relation with energy intake, as shown with hormonal shifts
during the menstruation/ovulation cycle [52], may par-
tially contribute to young women's ability to control their
weight vs. increasing tendency toward obesity with meno-
pause. Similarly, premenopausal women's capacity for re-
moval of very-low-density lipoprotein (VLDL) cholesterol
from the plasma is greater compared to men's and to
menopausal women's, with resultant rise in the latter's
plasma lipoproteins and associated disease risk [55].
However, with increasing obesity levels in young
women, MetS and related risks may be manifested earl-
ier in this age group, suggesting that weight gain at an
early age predisposes young women to risks as seen with
menopausal obesity, due to their earlier and higher rates
of obesity-related accumulation of metabolic risks than
in men [56].
Women-specific chronological perspectives on health risk
Whereas women were previously considered at high
CVD risk if their 10-year predicted risk of CHD was
more than 20%, their cumulative lifetime risk may be
underestimated because of delayed manifestation to
postmenopausal age. This may be related to the peak
tendency toward weight gain occurring around 50 years
of age [57], associated with higher rates of gain [58],difficulty maintaining body weight [59], and tendency to-
ward weight regain following weight loss diets, which is
highly predictive of later risk [60]. Updated guidelines
from the American Heart Association note that newer
risk formulas are available to predict 10- and 30-year
risks for all CVD events, including CHD, stroke, and
heart failure; for example, the 10-year predicted risk for
CHD of >20% now includes women aged >60 years with
elevated CRP as candidates for medication intervention,
even if they do not have heart disease or elevated lipid
levels. Other inflammatory/oxidative medical conditions,
such as rheumatoid arthritis, systemic lupus, and a his-
tory of pre-eclampsia, gestational diabetes, or pregnancy-
induced hypertension, have also been added to the at-risk
category. Such additional new high-risk criteria for CVD
in women suggest a differential definition of women-
specific recommendations for lifestyle and healthcare
according to the long-term effectiveness-based paradigm,
beyond the evidence-based approach to immediate risk
measures [61].
Women-specific healthy lifestyle aspects
Apart from smoking and/or exposure to environmental
(‘second-hand’) tobacco smoke and alcohol, obesity—
the suggested leading cause of decreasing gender gap in
LE [14] — is associated with most of women's risk fac-
tors for MetS and related chronic diseases, i.e. excess
body weight/obesity (BMI ≥25), waist circumference
(WC ≥35 in. or >88 cm), with elevated blood pressure
(≥120/80 mmHg), dyslipidaemia (LDL cholesterol ≥100
mg/dL, high-density lipoprotein (HDL) cholesterol <50
mg/dL, triglycerides (TG) ≥150 mg/dL, and non-HDL
cholesterol ≥130 mg/dL) [61], and dysglycaemia [62].
Long-accepted exacerbating factors remain as they were:
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moderate-vigorous exercise with an aerobic element)
and dietary factors, including low intake of fruits and
vegetables, whole-grain/high-fibre foods, and n-3 poly-
unsaturated fatty acid (PUFA; i.e. from n-3 PUFA-rich
fisha or from supplements), with high intake of saturated
fatty acid (SFA), cholesterol, alcohol, sodium, sugar, and
trans-FA (tFA) [61]. Low socioeconomic/cultural status
is another risk factor highly associated with increased
obesity, especially in women—found to be key in a re-
cent re-evaluation of the United States Mortality File
[63]—and in low- and medium-developed countries [64],
requiring specific considerations and economic and cul-
tural approaches that are beyond the scope of this
manuscript.
Healthy lifestyle in women that was associated with a
significantly reduced risk of total and ischaemic stroke
[65] consisted of no smoking, low BMI (≤22), moderate
alcohol consumption (4–10.5 drinks per weekb), regular
exercise (more than four times per week), and a healthy
diet, incorporating high fibre, folate, and n-3 PUFA, with
generally high PUFA/SFA ratio, and low tFA and gly-
caemic load (GL). Adherence to these lifestyle guidelines
could dramatically reduce the risk of CHD by approxi-
mately 82% [66]. Additionally, adherence to the American
Cancer Society's prevention guidelines—including for
BMI, physical activity, diet, and alcohol consumption—
lowered the risk of cancer and all-cause mortality in non-
smokers [67]. Further detailed recommendations for pri-
mary prevention included adjusted intake of meats and
fatty foods—especially sources of n-6 and n-3 PUFA—add-
ing olive oil, selected vegetables, and citrus fruits, and
adequate body fat/lean mass proportions [68]. A dietary
pattern high in fruit and low-fat dairy and low in white
bread, processed meat, margarine, and soft drinks was
suggested to help prevent abdominal fat accumulation
[69]. The above suggests that major Western diseases share
a common metabolic-nutritional basis and thus require
similar preventive measures. However, the alcohol link to
cancer risk [70-72] vs. benefits to heart health and diabetes
[73] is a reminder that the specificity of foods and risk
factors should not be overlooked, especially with regard to
the gender aspect [70,71,74,75]. The Mediterranean diet
that has repeatedly demonstrated an advantage against
Western diseases and was further suggested as a nutritional
framework for the predictive, preventive, and personalised
medicine (PPPM) approach [76] can be effectively adapted
and applied to various metabolic states, including those
associated with gender-specific risks.
Women-specific aspects of weight management
The general combination of reduced calorie diets and
exercise (both aerobic and resistance) [77] was repeatedly
confirmed in both sexes to be effective in musclepreservation, preferential reduction of abdominal vs. sub-
cutaneous adipose tissue, and improvement in fitness ca-
pacity compared to diet alone [78]. However, such a
combination, which was further associated with a twofold
greater improvement in insulin action compared with diet
alone in men [79], did not show similar effectiveness in
women [80], in whom exercise alone, even without caloric
restriction and/or weight loss, was associated with reduced
total and abdominal obesity and insulin resistance [81].
Women's fat loss, primarily subcutaneous vs. intra-
abdominal in men, yields much smaller improvements
in their specific risk factors, such as TG and HDL cho-
lesterol levels, compared to men losing the same amount
of weight/fat, but mostly abdominal [82]. Though WC is
known to be positively associated with diabetes in both
sexes, increasing WC was more closely associated with
diabetes in women than in men [83], which may suggest
higher sensitivity of WC as a metabolic measure in
women. The above suggests women's need for specific
metabolic emphases in obesity management, beyond
BMI and weight loss diet per se, vs. their specific risks
and chronological aspects compared to men's achieving
better risk reduction already through weight loss and
dietary restriction [84].
Dietary macronutrients and metabolic aspects
Fats A low-fat/cholesterol diet is routinely recom-
mended for individuals with elevated plasma LDL cho-
lesterol concentrations [85], though the combination of
a weight loss diet with exercise was less effective in im-
proving lipoprotein levels and LDL size in women than
in men [86]. A diet low in fat (25% kcal), SFA (7%), and
cholesterol (100 mg/day)—consistent with the NCEP
Step II diet—only partially attenuated the increase in
LDL cholesterol during menopause onset [87]. A diet
low in fat and high in vegetables, fruit, and whole grains
in the Women's Health Initiative study showed women
to have a smaller decrease in plasma lipoprotein levels,
similar decreases in particle sizes of LDL and HDL, but
greater reductions in postprandial TG levels compared
to men [85]. As increasing carbohydrate intake may in-
crease women's risk more than men's [88], a low-fat diet
with carbohydrate substitution may not necessarily pro-
vide women with the metabolic protection against
obesity-related risk that has been shown in men. These
findings may suggest a need for gender-based dietary
interventions to improve specific risk factors, with
awareness of women's differential response to strategies
that have successfully been targeted toward men [89].
Fatty acids Both essential fatty acids (EFA), linoleic acid
(LA; 18:2 n-6) and alpha-linolenic acid (ALA; 18:3 n-3),
are known for their lipidemic advantages, i.e. for
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with n-6 PUFA has demonstrated an advantage in redu-
cing LDL/HDL and TC/HDL ratios and TG levels, thus
improving metabolic factors and related effects in both
men and women. However, the unsaturated character of
PUFA may be associated with greater lipid and LDL oxi-
dation, especially with inflammation, i.e. facilitated by
high n-6 proinflammatory eicosanoids, believed to play a
key role in chronic diseases and accelerated ageing in
conditions of a high-n-6 Western diet [90,91]. Essential
PUFA are further converted in the liver to LCPUFA, LA
into arachidonic acid (20:4 n-6), and ALA into eicosa-
pentaenoic acid (20:5 n-3) and docosahexaenoic acid
(22:6 n-3). Their conversion varies according to gender
and age, being highest in young women—especially dur-
ing pregnancy [92,93]—compared to males [94,95] and
declining with age along with levels of the rate-limiting
enzymes delta-5- and delta-6-desaturases, more in
women than in men [96]. Desaturase activity is reduced
with high SFA intakes [97] and cholesterol [98] and
increased with a high-n-3 PUFA and/or MUFA diet [97].
LA (n-6) and ALA (n-3) share and compete for rate-
limiting conversion enzymes, emphasizing the importance
of the n-6/n-3 PUFA ratio for health and sex-related dif-
ferential predisposition. Women's higher production of
eicosanoids from either dietary n-6 or n-3 PUFA, which
are pro- and/or anti-inflammation/coagulation/carcino-
genesis, respectively, yields stronger implications for dif-
ferential CVD and cancer pathophysiology and clinical
outcomes, corresponding to their dietary PUFA ratios, as
compared to men's.
An ‘n-6 Gender Paradox’ hypothesis’ was proposed,
based on the Israeli case study of women's higher risk
with n-6 PUFA vs. men's benefit. Here, women's worse
health ranking vs. men's relative advantage in conditions
of high dietary n-6 PUFA (10–12% kcal) [99] led to the
unexpected observation of low national health status,
previously defined as the ‘Israeli Paradox’ [100,101]. The
above suggests that with the same diet, at certain high
levels of n-6 PUFA, women's greater transformation to
eicosanoids with proinflammatory, carcinogenic, aggre-
gatory characteristics may put them at greater risk com-
pared to men, who may benefit due to lower EFA
transformative capacity. In a recent Danish epidemio-
logical study, an n-6 PUFA increase was associated with
weight gain and increased WC in women, while the
opposite was shown in men [102], which could further
support a differential response and high-n-6 risk for
women vs. men's advantage.
Carbohydrates and glycaemic effects High carbohy-
drate intake may be associated with a disadvantage for
the lipid profile, including high TG and VLDL, especially
in overweight postmenopausal women [103], reflectingthe high impact of insulin on their lipid metabolism
[38]. Concurrent decreased LDL particle size further
explains the link between high dietary carbohydrates and
women's CVD risk [104].
While in men replacing SFA with carbohydrate from
grains, vegetables, legumes, and fruit effectively reduced
total and LDL cholesterol blood levels [87], only a mode-
rate reduction was observed in women, with lesser effects
on CVD [89]. Replacement of SFA by carbohydrates, espe-
cially refined sources and ‘added sugars’, increases plasma
TG and small LDL particles and reduces HDL, which are
of particular concern in the context of the increased
prevalence of obesity and insulin resistance, all especially
critical for women [88].
In the EPICOR study, women in the highest quartiles of
carbohydrate intake, GI, and GL had a significantly greater
risk of CHD (by about twofold) than those in the lowest
quartile, while a lesser association was found in men [88].
A twofold increased CHD risk with high GL, most evident
among women with BMI ≥23, was found in follow-up re-
search over a 10-year period (729,472 person-years), but
not among normal-weight women [105]. Dietary GI and
GL were progressively associated with CHD in various
populations [106] and with plasma CRP levels, in general
and in healthy middle-aged women [107], suggesting an
explanatory link between women's ischaemic heart disease
with overweight and their susceptibility to insulin resis-
tance [108].
Proteins Although energy restriction alone often leads
to weight loss, the composition of the lost tissue also
matters, and high loss of lean mass could have delete-
rious metabolic consequences. This is especially critical
for women with innately low initial FFM, a tendency to-
ward a plateau in weight loss, and for later weight regain
[56,109]. Moreover, because skeletal muscles play roles
in energy metabolism, their potential loss in the weight
reduction process emphasises the need to focus on the
composition of the lost weight for preservation of lean
tissue, rather than relating merely to scale weight. Here,
higher protein, lower carbohydrate, and GI energy-
restricted diets have been shown to help offset women's
lean mass loss, especially when associated with resist-
ance exercise [110].
A high-protein diet was more effective for women,
who lost nearly twofold more total and abdominal fat
compared with women on the low-protein diet, whereas
in men, there was a lesser difference in fat loss between
diets; in both sexes, a high-protein diet caused greater
total and LDL cholesterol reductions [111,112], with no
effect on blood TG [112]. A high-protein (≥40% kcal)
diet was also more effective in women with polycystic
ovary syndrome, yielding a greater reduction in body
weight, body fat, WC, and blood glucose than the
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high-protein diet (1:1 vs. 3:1 carbohydrate/protein ratios)
was superior to a low-fat and high-carbohydrate diet, with
or without an aerobic/resistance training programme, for
effective weight loss, nitrogen balance, improved body
composition, and reduced risk factors for the MetS in
overweight and obese women [114]. A high-protein, high-
dairy, energy-restricted diet plus exercise combination was
further linked to improved energy-protein balance com-
pared to a lower dairy, higher protein diet, as shown by
greater losses of total and visceral fat, smaller losses of
lean mass, and increases in body strength despite identical
weight loss [110]. Moreover, during adolescence, higher
dairy product intake was associated with a lower risk of
later adult type 2 diabetes, partially explained by the per-
sistence of the consumption pattern through adulthood
and results of a cumulative high-protein, high-dairy effect
[115]. A high-protein, low-carbohydrate diet was also
found to reduce blood glucose, insulin, and lactate levels
and to prevent cancer initiation and to slow tumour
growth [113].
Physical activity
Sedentary life, a characteristic of the modern environment,
is a known health risk factor. Moreover, increased sitting
time was recently found to be an active and independent
risk factor, positively associated with fasting insulin, leptin,
leptin/adiponectin ratio, CRP, and IL-6 in women, more
than in men. These associations remained significant after
additional adjustment for total moderate- to vigorous-
intensity physical activity [116]. In contrast, physical activ-
ity was inversely correlated with BMI, insulin levels, CRP,
leptin, WC, and body fat percentage in young and middle-
aged women, suggesting ‘anti-age’-related increases in the
above measures with physical activity that may potentially
counteract sedentariness and age effects in women [117].
Additionally, non-exercise activity, all activity that is not
sleeping, eating, or sports-like exercise, could be a critical
component for increasing energy expenditure and meta-
bolic rate, maintaining FFM, and preventing weight gain,
obesity, and sedentariness-related risk [81].
As women oxidise proportionately more lipids and less
carbohydrates and protein compared to men, and as
they do not build muscle glycogen with a carbohydrate
load but rather more body fat, their exercise-related fat
loss is critical for improved body composition [116,118].
Exercise-associated increases in lipolysis in abdominal
visceral fat and reduction of their related risks, despite a
lower response from luteal-femoral adipose tissue,
explains the higher exercise-related benefit and reduc-
tion in women's morbidity and mortality, independent of
BMI or weight loss, compared to men [119].
A combined exercise and weight loss diet was asso-
ciated with the greatest reduction in women's total,abdominal, and subcutaneous fat; reduced insulin resist-
ance (≈32%) in the exercise plus diet group, but not with
diet alone; and WC closely reflecting the benefits of re-
ducing abdominal obesity, whereas BMI alone may mask
the positive effects of exercise [81]. The correlation be-
tween recreational physical activity and reduction in risk
of breast cancer recurrence and mortality, which are
known to be associated with increased abdominal obe-
sity, further support the special importance of physical
activity to women [120].
Conclusions
Findings showing women's differential metabolic respon-
ses have suggested a gender effect on biochemical-
endocrinological patterns, metabolic mechanisms, and
risk factors, emphasising the importance of more
gender-specific prevention strategies. This is especially
relevant vs. environmental changes and the obesogenic
epidemic, with women's lead in earlier and higher
obesity rates and related disease risk, though with
manifestation mostly delayed to menopausal age.
Women's differential metabolic responses compared to
men throughout the life cycle strongly suggest a need for
gender-specific strategies against obesity and chronic
diseases such as CVD, diabetes, MetS, and cancer, includ-
ing differential metabolic biomarkers and chronological
patterns across the spectrum of diseases. This is especially
relevant in light of women's unique vulnerability to mod-
ern environmental pressures, including increased seden-
tary lifestyle, obesity, glycaemic load, dietary n-6/n-3
PUFA ratio, and transitional socioeconomic and psycho-
social stresses. Applying men's knowledge to women's
practice may not only yield lower benefits, but may also
further enable exacerbation of metabolic imbalance, i.e.
substituting dietary fat with carbohydrates and/or repeated
weight loss diets without considering the preservation
of women's lean body mass, which may gradually reduce
their metabolic balance and resistance to Western
diseases, despite greater benefits for men. Further, the dif-
ferential response to higher protein/carbohydrate ratios, to
low glycaemic load, as well as to exercise vs. sedentary life-
style should be considered for differential prevention and
intervention strategies. A differential time perspective is
also required, considering females' much earlier fat accu-
mulation process, which presets the metabolic patterns for
later increases in obesity risks compared to males. Even a
measure considered basic, i.e. BMI, may underestimate
the female obesity state and rather masks fat percentage,
which could better reflect the metabolic obesity state,
which is more closely associated with obesity risk, espe-
cially with android type, manifested by abdominal sub-
cutaneous and visceral fat and high WC.
As CVD prevention shares recommendations with those
of cancer as well as other chronic Western diseases,
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metabolic risks, biomarkers, and chronological patterns
across the spectrum of conditions, beyond specific diagno-
sis, prevention, and intervention. Much epidemiological
study and clinical research are needed, including interven-
tional trials for attaining women-specific understanding of
metabolic risks and epidemiological evidence-based recom-
mendations for designing targeted nutritional strategies
within the context of gender nutrition and the PPPM
approach to health- care.
Endnotes
a Pregnant women are generally counselled to avoid
eating types of fish with the potential for the highest
level of mercury contamination (i.e. shark, swordfish,
king mackerel, or tile fish).
b The American Cancer Society's recommendation for
alcohol intake was recently reduced to no more than
one drink per day for women and two for men [121], in
response to findings of alcohol-cancer links [74] even
with intake previously considered ‘low’ [61,70,71,74,75].
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